Background
What do we already know about this topic?
- Atopic dermatitis (AD) is an interleukin-13 (IL-13) dominant disease.1
- Lebrikizumab is a novel, high-affinity monoclonal antibody that selectively binds to IL-13.2
- ADvocate1 and -2 are Phase 3 trials to evaluate efficacy and safety of monotherapy in adolescents and adults with moderate-to-severe AD.
How was this study conducted?
- Patients who responded to lebrikizumab 250 mg Q2W at the end of the 16-week induction were re-randomized to lebrikizumab Q2W or Q4W, or placebo for 36 weeks.
- Topical steroids were allowed from Week 16–52 as rescue therapy.
- Safety results include patients who received at least one dose in either the induction or maintenance treatment periods.